Savan Devani

Overview

Savan Devani is an angel investor and entrepreneur based in San Francisco, California. He is the Founder and CEO of BioTrillion, a health technology company developing a digital biomarker platform called BioEngine4D to digitally detect developing diseases. Prior to founding BioTrillion, Savan spent over 12 years in healthcare investment banking at Citigroup and Deutsche Bank, where he led 40 financing and M&A deals totaling over $35 billion in value across the drug, diagnostic, and device sectors. His clients included Amgen, Eli Lilly, Fosun, Masimo, Medtronic, Pacific Biosciences, and Xenoport. Savan began his career as a bioengineer at Life Technologies. He holds a B.S.E. in Bioengineering from the University of California at Berkeley and an M.S.E. in Bioengineering from the University of Pennsylvania. After a personal experience with his mother's sudden diagnosis of stage IVb cancer, Savan founded BioTrillion to address the need for early disease detection. At BioTrillion, Savan focuses on developing innovative health technologies that leverage digital biomarkers for early disease detection. His investment strategy centers on early-stage ventures in sectors such as health care, wearables, computer vision, deep tech, wellness, enterprise software, life sciences, artificial intelligence, information technology, software, biotechnology, neuroscience, fintech, computer science, health diagnostics, digital health, medical, big data, media and entertainment, and machine learning. Savan's approach combines his extensive experience in healthcare investment banking with his entrepreneurial vision to support companies that aim to transform healthcare through technological innovation. Savan's track record includes leading significant financing and M&A deals, totaling over $35 billion in value, across various sectors, including drug, diagnostic, and device technologies. His clients have included major corporations such as Amgen, Eli Lilly, Fosun, Masimo, Medtronic, Pacific Biosciences, and Xenoport. This extensive experience has equipped him with a deep understanding of the healthcare industry's complexities and the potential for technological advancements to drive meaningful change. His investment philosophy emphasizes supporting companies that are at the forefront of innovation and have the potential to make a significant impact on healthcare delivery and patient outcomes.

Investment Focus

• Early Stage Venture
• Health Care
• Wearables
• Computer Vision
• DeepTech
• Wellness
• Enterprise Software
• Life Science
• Artificial Intelligence (AI)
• Information Technology (IT)
• Software
• Biotechnology
• Neuroscience
• FinTech
• Computer Science
• Health Diagnostics
• Digital Health
• Medical
• Big Data
• Media and Entertainment

Portfolio Companies